Tempus AI stock (TEM)
Tempus AI stock (TEM) closed at $75.89 on Nov 12, 2026, up 28.5% year to date, for a market capitalization of $13.8B. Revenue of $1.5B over the last twelve months; in the latest quarter, revenue up 23.1% year on year, with a -13.8% operating margin. Filed with the SEC, as of Sep 30, 2026.
- Last close
- $75.89 (2026-11-12)
- Year to date
- +28.5%
- 52-week range
- $40.77 – $89.09
- Market capitalization
- $13.8B
- Dividend yield
- None
- Revenue (TTM)
- $1.5B
- Revenue growth
- +23.1%
- Operating margin
- -13.8%
- Price / sales
- 9.2
- EV / revenue
- 9.7
- Figures as of
- 2026-09-30
- Named institutional holders
- 97
- Declared ownership
- 71.6% – 83.0%
- Exchange
- Nasdaq
- Headquarters
- Chicago, Illinois
- Fiscal year ends
- December
- Industry (SEC)
- Services-Computer Programming, Data Processing, Etc.
- Registered with the SEC as
- Tempus AI, Inc. (CIK 1717115)
Who owns Tempus AI?
97 institutional holders named from SEC filings, together declaring between 71.6% and 83.0% of the shares outstanding, as of Nov 2, 2026. The largest named holders of Tempus AI stock are Eric P. Lefkofsky (19.8%), Vanguard (8.5%), ARK Investment Management LLC (4.7%), BlackRock (4.5%) and BAILLIE GIFFORD & CO (3.8%). From Mar 31, 2026 to Jun 30, 2026, 103 managers opened a position, 145 added, 119 reduced and 57 sold out; the biggest sellers were GC Wealth Management RIA, LLC and VOLORIDGE INVESTMENT MANAGEMENT, LLC, the biggest buyers Goldman Sachs and Citadel.
Tempus AI shareholders: institutions, insiders and funds
Tempus AI dividend
Tempus AI does not pay a dividend: none in its price history since Sep 23, 2023.
About Tempus AI
Tempus is a technology company focused on healthcare that straddles two converging worlds. We strive to combine deep healthcare expertise, providing next-generation diagnostics across multiple disease areas, with leading technology capabilities, harnessing the power of data and analytics to help personalize medicine. Unlike traditional diagnostic labs, we can incorporate unique patient information, such as clinical, molecular, and imaging data, with the goal of making our tests more intelligent and our results more insightful. Unlike other technology companies, we are deeply rooted in clinical care delivery as one of the largest sequencers of cancer patients, and patients with other diseases, in the United States.
Tempus AI's own description, from its annual report (Form 10-K, filed Feb 24, 2026), Item 1. Business. Read the filing on sec.gov
Tempus AI is headquartered in Chicago, Illinois. It is registered with the SEC as Tempus AI, Inc. (CIK 1717115); its fiscal year ends in December and its shares trade on the Nasdaq. Tempus AI is one of the artificial intelligence (AI) and semiconductor companies tracked on Silicon Floor, in the AI software segment, with live prices, SEC filings, financial statements, institutional ownership and dividends.
Latest reported quarter
In its quarter ended Sep 30, 2026 (filed Nov 2, 2026), Tempus AI reported revenue of $411.5M, operating income of -$56.9M and net income of -$14.9M.
Latest SEC filings
- 8-K: Earnings released (2.02), Nov 2, 2026
- 424B3: Merger prospectus: shares issued as consideration (424B3), Oct 21, 2026
- 4: Insider sale (CEO, Data), Aug 21, 2026
- 4: Insider sale (CEO and Chairman), Aug 21, 2026
More on Tempus AI
- Who owns Tempus AI
- Tempus AI insider trading
- Tempus AI relationships
- Tempus AI dividend
- Tempus AI financials
- Tempus AI technicals and short interest
Filed figures, quarter by quarter
- Tempus AI revenue by quarter, with the filing behind each
- Tempus AI operating income by quarter, with the filing behind each
- Tempus AI net income by quarter, with the filing behind each
